Detalhe da pesquisa
1.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
2.
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Toxicol Appl Pharmacol
; 262(1): 1-10, 2012 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22676972
3.
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Cancer Chemother Pharmacol
; 85(5): 959-968, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32296873
4.
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Leukemia
; 33(11): 2575-2584, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30967620
5.
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lancet Gastroenterol Hepatol
; 4(9): 711-720, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31300360
6.
Rhabdomyosarcoma of the maxillary gingiva.
J Periodontol
; 78(9): 1839-45, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17760557
7.
Current issues in adolescent and young adult cancer survivorship.
Cancer Control
; 15(1): 55-62, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18094661
8.
Practical issues of intraoperative frozen section diagnosis of bone and soft tissue lesions.
Cancer Control
; 15(1): 7-12, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18094656
9.
Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.
Cancer Control
; 15(1): 47-54, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18094660